1. Home
  2. GENC vs IMUX Comparison

GENC vs IMUX Comparison

Compare GENC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gencor Industries Inc.

GENC

Gencor Industries Inc.

HOLD

Current Price

$15.01

Market Cap

219.1M

Sector

Industrials

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.12

Market Cap

188.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENC
IMUX
Founded
N/A
2016
Country
United States
United States
Employees
N/A
66
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.1M
188.8M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
GENC
IMUX
Price
$15.01
$14.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$17.60
$36.00
AVG Volume (30 Days)
29.6K
229.8K
Earning Date
02-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
8.08
38.00
EPS
0.50
N/A
Revenue
$48,943,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$25.51
N/A
P/E Ratio
$29.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.22
$0.51
52 Week High
$17.40
$15.77

Technical Indicators

Market Signals
Indicator
GENC
IMUX
Relative Strength Index (RSI) 50.00 62.08
Support Level $14.57 $0.74
Resistance Level $15.62 $15.77
Average True Range (ATR) 0.47 1.20
MACD 0.03 -0.25
Stochastic Oscillator 47.33 60.66

Price Performance

Historical Comparison
GENC
IMUX

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: